Skip to main content
Caplight Logo









Elixiron Immunotherapeutics

Elixiron Immunotherapeutics

Public

Elixiron Immunotherapeutics is now publicly traded

The data on this page reflects Elixiron Immunotherapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Jun 12, 2025

Total Funding Raised

$70M

Company Overview

Elixiron Immunotherapeutics is a clinical-stage biotechnology company that develops precision immunotherapies for neuroinflammatory diseases, autoimmune diseases, and cancer.

AI Layer

Application

Keywords

immunotherapydrug discoverytherapeutic vaccinemonoclonal antibodybiotechoncologyinflammatory diseaseai drug discoveryclinical-stage biotechbiopharmaprecision medicinedrug licensingin silico drug designmulti-omics

Elixiron Immunotherapeutics Comparables

Compare Elixiron Immunotherapeutics with similar companies based on industry and business-model similarity.

Elixiron Immunotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pilatus Biosciences
73%
SynOx Therapeutics
57%

Elixiron Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 12, 2025
GrantJul 12, 2022
Series A ExtensionAug 23, 2021
GrantAug 25, 2020
Series AJul 31, 2019

Key People

Founding team and executive leadership

Cheng-Lung KU

Chief Science Officer, Co-Founder

Founding Team

Elixiron Immunotherapeutics Investors

Notable investors and investment history

Elixiron Immunotherapeutics investors
InvestorRounds
Taiwania CapitalSeries A, Series A Extension
Fubon Financial Holding Venture CapitalSeries A Extension
CDIB Capital InternationalSeries A
China Investment & Development Company, LimitedSeries A Extension
Alzheimer's AssociationGrant
Fubon Financial HoldingsSeries A Extension

Recent news

Latest coverage and updates

  • attends_eventJul 14, 2026

    Elixiron Immunotherapeutics, Inc. attended event BIO Asia-Taiwan 2026 Special Forum on Jul 14th '26.

  • attends_eventJul 13, 2026

    Elixiron Immunotherapeutics, Inc. attended event Investment Summit on Jul 10th '26.

Elixiron Immunotherapeutics Filings

Explore SEC and related filing metadata, where available.

Elixiron Immunotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

Headquarters—
Employee Range15
Year Founded2017
Last FundingJun 12, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?